Medtronic (NYSE:MDT) shares hit a 52-week high today for the 2nd day in a row, perhaps buoyed by news of a European regulatory approval for 1 of its CoreValve replacement heart valves.

MDT shares peaked yesterday at $65.91 yesterday before subsiding to a $65.54-per-share close. Shares rose to $66.21 today and were trading at $65.99 each as of about 2:30 p.m. Eastern.

Investors may be reacting to positive news this week for Medtronic’s CoreValve Evolut R transcatheter aortic valve implant, which won CE Mark approval in the European Union earlier this week.

Today Medtronic announced the 1st implantations in a U.S. trial of the device, the latest iteration in the CoreValve line acquired for $700 million plus milestones back in 2009.